Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. (XERS) filed a Current Report on Form 8-K dated June 3, 2025. The filing announces the Company's first Analyst and Investor Day, held in New York City on the same date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose the occurrence of the Investor Day and the availability of related presentation materials.
Material Changes
No material changes to financial position or operations are reported in this specific filing. The primary event is the dissemination of strategic information via an investor presentation.
Guidance, Outlook, and Management Commentary
- Investor Presentation: Senior management delivered a slide presentation (Exhibit 99.1) to investors. The text of this presentation is not included in the filing body but is referenced as an exhibit.
- Press Release: A press release announcing the event (Exhibit 99.2) is attached.
- Forward-Looking Statements: The filing explicitly states that the information furnished, including the presentation and press release, is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation) for specific clinical updates, pipeline milestones, and financial guidance not detailed in this summary.
- Verify the content of Exhibit 99.2 (Press Release) for official announcements regarding the Investor Day outcomes.
- Check the Company's website (www.xerispharma.com) under the "Investors" tab for the presentation, noting the disclaimer that website content is not incorporated by reference into this 8-K.
- Confirm that no new debt or liquidity events were triggered by the event, as none are reported in this filing.